U.S. markets closed

Immuron Limited (IMRN)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.6500-0.1700 (-6.03%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close2.8200
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range2.6500 - 2.8300
52 Week Range1.4810 - 5.9600
Avg. Volume917,758
Market Cap15.643M
Beta (5Y Monthly)1.14
PE Ratio (TTM)N/A
EPS (TTM)-0.4400
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for IMRN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Immuron Limited
    Daily – Vickers Top Insider Picks for 12/11/2023The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
  • GlobeNewswire

    Immuron Travelan® sales continued strong growth

    Sales Highlights: Global FYTD Mar 2024 AUD$3.6 million up 154% on (prior comparative period) pcpMar 2024 Quarter AUD$1.3 million up 51% on pcp and 75% on last quarter Australia FYTD Mar 2024 AUD$2.8 million up 234% on pcpMar 2024 Quarter AUD$0.9 million up 66% on pcp and 99% on last quarter USA FYTD Mar 2024 AUD$0.8 million up 35% on pcpMar 2024 Quarter AUD$0.3 million up 7% on pcp and 18% on last quarterSales commenced on MELBOURNE, Australia, April 10, 2024 (GLOBE NEWSWIRE) -- Immu

  • Simply Wall St.

    We're Not Very Worried About Immuron's (ASX:IMC) Cash Burn Rate

    We can readily understand why investors are attracted to unprofitable companies. For example, although made...

  • GlobeNewswire

    Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US

    Highlights: Immuron proceeding to Phase 3 registration strategy with the FDATravelan® topline clinical trial results demonstrate protective efficacy with single daily dose36.4% protective efficacy against Enterotoxigenic Escherichia coli (ETEC) induced moderate to severe diarrhea was observed in the Travelan® group compared to the placebo group (primary endpoint)66.7% protective efficacy against ETEC induced severe diarrhea was observed in the Travelan® group compared to the placebo group (secon